Biopharma Script Tracker—Trends vs. Consensus, Accounting for Seasonality

Research evidence excerpt

Biopharma Script Tracker—Trends vs. Consensus, Accounting for Seasonality

Equity Research

Industry Update — June 5, 2026

Large Cap Pharmaceuticals

Biopharma Script Tracker—Trends vs.

Consensus, Accounting for Seasonality

Our Call Mohit Bansal

For week ending 5/29, LLY's incretin scripts appear to be trending ahead of cons. Oral Equity Analyst | Wells Fargo Securities, LLC

Mohit1.Bansal@wellsfargo.com | 212-214-8025

GLP-1s make up ~14% of obesity GLP-1 TRx with Foundayo +6% vs. oral Wegovy -8% w/

Sadia Rahman, PhDw. GILD's Yeztugo looks slightly behind, while Leqembi is trending slightly ahead.

Equity Analyst | Wells Fargo Securities, LLC

Sadia.Rahman@wellsfargo.com | 646-584-6948

LLY incretin franchise tracking ~6% ahead QTD. For week ending 5/29, Mounjaro and Susan Chor

Trulicity EUTRx decreased 5.4% and 7.1% w/w, respectively, while Zepbound total EUTRx Associate Equity Analyst | Wells Fargo Securities, LLC

decreased 7.4% w/w. Ozempic EUTRx decreased 4.5% w/w, while Wegovy decreased 6.0% Susan.Chor@wellsfargo.com | 212-214-5010

w/w. Decreases potentially driven by Memorial Day holiday. Zhengxi Sun, PhD

Associate Equity Analyst | Wells Fargo Securities, LLC

Exhibit 1 - LLY Diabetes/Obesity Scripts Quarter-to-Date Zhengxi.Sun@wellsfargo.com | 929-793-1007

2Q26 QTD Implied William Zhang

1Q26 1Q26 Implied IQVIA Price 2Q26 Beat / Associate Equity Analyst | Wells Fargo Securities, LLC

Reported Adjustments Demand Growth Impact Sales US Cons. (Miss)% William.Zhang@wellsfargo.com | 929-697-5075

Mounjaro $4,232 $100 $4,132 11% -3% $4,461 $4,282 4.2%

Zepbound* $4,134 $150 $3,984 28% -3% $4,947 $4,571 8.2%

Trulicity $600 $0 $600 -5% -3% $551 $555 (0.6%)

Total ($M) $8,716 $9,960 $9,408 5.9%

Source: Wells Fargo Securities, LLC estimates, IQVIA (accessed 06/05/26), Visible Alpha